reports
- Fehmi Ben Naamane
- Johanna Jourdain
- Fehmi Ben Naamane
- Johanna Jourdain
Groupe Casino : nombre total de droits de vote et d’actions au 30-09-2...
Groupe Casino : nombre total de droits de vote et d’actions au 30-09-2025 Informations relatives au nombre total de droits de voteet d’actions composant le capital socialau 30 septembre 2025 (article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Nombre d’actions composant le capitalNombre total de droits de voteNombre total de droits de vote exerçables en assemblée générale400 939 713401 184 671400 731 845 * * ** Fait le 16 octobre 2025 à 17h30 Pièce jointe
- Jacob Mekhael
- Thibault Leneeuw
- Wim Lewi
- Jacob Mekhael
UCB Publishes Fintepla LGS open-label extension results in journal
UCB announced that the final analysis of an open-label extension (OLE) study on Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS) was published in the Epilepsy and Behavior journal. This follows previous presentations at a medical conference and highlights the long-term sustained benefit and lack of new or unexpected safety signals, which we view as supportive of Fintepla's benefit in this patient population. For reference, Fintepla is one of UCB's 5 growth drivers, and we estimate peak s...
- Jacob Mekhael
UCB Publishes pyrimidine nucleo(s)(t)ide therapy results in TK2d in jo...
UCB announced the publication of results from a multicenter retrospective chart review study of pyrimidine nucleo(s)(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) in Neurology, which are in line with previous reports of the positive outcomes on survival and functional outcomes presented at a medical conference earlier this year. Note that TK2d is an ultra-rare genetic mitochondrial disease with no approved therapies, and has a prevalence of 1.64 per 1m people. Doxecitine an...
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Lewi
- Anthony Dick
- Michael Foundoukidis
GET GETLINK SE
SGO COMPAGNIE DE SAINT-GOBAIN SA
MT ARCELORMITTAL SA
CA CARREFOUR SA
BEKB BEKAERT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SK SEB SA
SSAB A SSAB AB CLASS A
RHM RHEINMETALL AG
SZG SALZGITTER AG
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
HEN3 HENKEL AG & CO. KGAA PREF
NDA AURUBIS AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
ABI ANHEUSER-BUSCH INBEV SA/NV
RIO RIO TINTO PLC
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
8TRA TRATON SE
ENR SIEMENS ENERGY AG
VUL VULCAN ENERGY RESOURCES
SHEL SHELL PLC
AAL ANGLO AMERICAN PLC
- Anthony Dick
- Michael Foundoukidis
GET GETLINK SE
SGO COMPAGNIE DE SAINT-GOBAIN SA
MT ARCELORMITTAL SA
CA CARREFOUR SA
BEKB BEKAERT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SK SEB SA
SSAB A SSAB AB CLASS A
RHM RHEINMETALL AG
SZG SALZGITTER AG
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
HEN3 HENKEL AG & CO. KGAA PREF
NDA AURUBIS AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
ABI ANHEUSER-BUSCH INBEV SA/NV
RIO RIO TINTO PLC
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
8TRA TRATON SE
ENR SIEMENS ENERGY AG
VUL VULCAN ENERGY RESOURCES
SHEL SHELL PLC
AAL ANGLO AMERICAN PLC
- Christophe Chaput
- Christophe Chaput
UCB SA: 2 directors
Two Directors at UCB SA sold after exercising options/sold 8,000 shares at between 248.275EUR and 252.680EUR. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compan...
- Carole Braudeau
- Carole Braudeau
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Wim Lewi
- Jacob Mekhael
UCB Galvokimig R&D call highlights potential in AD, model update
Yesterday, UCB hosted an R&D call to highlight the phase 2a data for galvokimig from EADV 2025, which showed strong efficacy in atopic dermatitis (AD), with a 52.6% placebo-adjusted EASI75 response at week 12, outperforming other biologics in cross-trial comparison. The KOL highlighted galvokimig's potential for broad positioning across the AD treatment paradigm if the early data is replicated in later stage trials, especially as a monotherapy. We update our model for UCB, which brings us to a n...
- Baptiste Salaville
- Bruno Cavalier
- Konrad Zomer
SU SCHNEIDER ELECTRIC SE
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
ABB ABB LTD.
EL ESSILORLUXOTTICA SA
WKL WOLTERS KLUWER NV
BRBY BURBERRY GROUP PLC
KER KERING SA
BAS BASF SE
UCB UCB S.A.
01913 PRADA S.P.A.
MONC MONCLER SPA
YPSN YPSOMED HOLDING AG
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
PUIG PUIG BRANDS
- Baptiste Salaville
- Bruno Cavalier
- Konrad Zomer
SU SCHNEIDER ELECTRIC SE
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
ABB ABB LTD.
EL ESSILORLUXOTTICA SA
WKL WOLTERS KLUWER NV
BRBY BURBERRY GROUP PLC
KER KERING SA
BAS BASF SE
UCB UCB S.A.
01913 PRADA S.P.A.
MONC MONCLER SPA
YPSN YPSOMED HOLDING AG
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
PUIG PUIG BRANDS
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.